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ABSTRACT
ANTIDEPRESSANT EFFECTS OF THE NTS1 AGONIST PD149163 IN THE
FORCED SWIM TEST
By
Lawrence Michael Carey IV
Neurotensin is a neuropeptide that influences monoaminergic neurotransmission
in areas of the brain involved in the pathophysiology of depression. The forced swim test
is a commonly used screening model for putative antidepressant medications. Drugs that
have antidepressant effects in humans reliably decrease the time animals spend in an
immobile posture in the forced swim test without increasing general locomotor activity as
measured in an open field test. The present study sought to examine the effects of the
neurotensin NTS1 receptor agonist PD149163 and the tricyclic antidepressant drug
imipramine on immobility in the forced swim test and on locomotor activity in an open
field in mice. PD149163 decreased the total time spent immobile at doses of 0.1 mg/kg
and 1.0 mg/kg, without increasing overall locomotor behavior in the open field test.
Imipramine produced a reduction in immobility at a dose of 10.0 mg/kg, but not at 1.0
mg/kg, without increasing locomotor activity. These results indicate that since drugs that
target the neurotensin system display antidepressant properties in rodent models of
depression they may represent a novel mechanism for treatment of depressive symptoms
in humans.
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INTRODUCTION

Depression is a serious medical condition that is estimated to affect roughly 1025% of women, and 5-12% of men (American Psychiatric Association, 2013).
Depression may occur at any age, but the average age of onset occurs during the mid
twenties (American Psychiatric Association, 2013). The time-course and duration of
symptoms is variable as some people will only experience isolated episodes of
depression, while others will have recurring episodes throughout their lives. Those who
develop more than one episode of depression are at a higher risk of developing
subsequent episodes later in life. Approximately 60% of individuals who experience one
major depressive episode will experience a second episode later in life. Approximately
70% of people who do develop a second episode will experience a third depressive
episode, and among those who experience a third episode, 90% will experience further
problems with depression (American Psychiatric Association, 2013). Several factors may
influence the development of depression, including alterations in several of the brain’s
monoaminergic neurotransmitter systems, genetics, substance abuse, and a variety of
other psychiatric conditions. The World Health Organization has estimated that
depression will constitute the second leading cause of illness-related disability by 2020
(Murray & Lopez, 1997). On a global scale, medications to treat depression are the third
highest selling class of drug (Celada et al., 2004), most of which target one or more of the
brain’s monoaminergic neurotransmitter systems. However, currently available
antidepressant medications do not adequately treat the disorder, and patient
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responsiveness to treatment is poor. Various studies have reported values ranging from
fewer than 50% to less than 28% of patients being effectively treated with one medication
alone (Kocsis, 2000, Trivedi, 2006, Fava, 2000). Subsequently, physicians are required to
prescribe a cocktail of medications. Furthermore, in the patients who did respond to
antidepressant treatment in these studies, symptom improvement was observable only
after 10-14 weeks. The protracted latency to the onset of therapeutic effects, as well as
the staggeringly low response rates, indicates the need for novel pharmacotherapies for
the treatment of depression.

The Monoamine hypothesis of depression
Much of what we know about the biological basis of depression has been inferred
from studying the effects that antidepressant drugs exert in the brain. Beacuse most drugs
that are effective at combating the symptoms of depression in humans alter
neurotransmission of one or more of the monoamine neurotransmitter systems, to date,
much of the research into the etiology of the disorder has focused on a monoamine-based
hypothesis of dysfunction. In the mid-1960’s depression began to gain recognition as a
medical disorder with organic causes. The monoamine hypothesis of depression states
that the symptoms of depression are caused by deficiencies in monoamine
neurotransmission, and by correcting these imbalances, the symptoms may be
ameliorated (Schildkraut, 1965).
The monoamines are a family of structurally related neurotransmitters that include
the catecholamines dopamine, norepinephrine, and epinephrine, and the indolamine
2

serotonin. Although these neurotransmitters differ widely in their distribution and types
of receptors they act upon, they share several characteristics that are of interest to the
etiology and treatment of depression. The monoamines are packaged into vesicles by the
vesicular monoamine transporter, of which two distinct subtypes exist. Vesicular
monoamine transporter type 1 (VMAT1) is primarily located in the periphery, while
vesicular monoamine transporter type 2 (VMAT2) is located in the central nervous
system (Masson et al., 1999). The packaging into vesicles is a crucial step in monoamine
neurotransmission, as it maintains the concentration gradient of monoamines by aiding in
their uptake from the extracellular space. This process also serves to protect them from
leakage and premature metabolism in the presynaptic terminal (Masson et al., 1999).
Alterations in VMAT2 may play a role in the genesis of depressive symptoms, as well as
an individual’s responsiveness to treatment (Valevski, 2010).
The monoamines also share similar mechanisms of degradation. Two different
enzymes are involved in the metabolism of monoamines: monoamine oxidase (MAO),
and catechol O-methyltransferase (COMT). MAO metabolizes dopamine, serotonin, and
norepinephrine, while COMT primarily metabolizes dopamine and norepinephrine. MAO
regulates monoamine neurotransmission by degrading monoamines, and in normally
functioning individuals MAO acts to preserve homeostasis of neurotransmitter levels in
the brain. When levels of monoamines increase, increases in MAO are also observed.
Likewise, when brain levels of monoamines decrease, MAO levels also decrease
(Schwartz, 2013). Therefore, dysfunctions in MAO levels indicate one possible avenue to
explain monoaminergic deficiencies observed in depression (Schwartz, 2013). COMTmediated degradation of dopamine may also play an important role in the genesis of
3

depressive symptoms, as individuals with altered levels of COMT activity have been
found to be at an increased risk for development of depression (Anytpa et al., 2013).
While the monoamines share several regulatory mechanisms regulating their release and
degradation, their specific receptor signal transduction mechanisms and neural regions
innervated by the individual neurotransmitters differ greatly. For these reasons, I will
consider each of the monoamine’s specific contributions to the generation of depressive
symptoms separately.

The role of dopamine in depression
Dopamine belongs to the catecholamine family of the monoamine
neurotransmitters and acts on five different subtypes of metabotropic receptors. These
five subtypes of receptors are designated the D1, D2, D3, D4, and D5 receptors. Two
separate families of dopamine receptors can be drawn from these five subtypes of
receptors, the D1-like family, which includes the D1 and D5 receptors, and the D2-like
family, which includes the D2, D3 and D4 receptors (Vallone et al., 2000).
The two dopamine receptor families differ in the downstream effects they exert
intracellularly upon activation. The D1-like family is generally considered to have
stimulatory effects on the cells that express them, while the D2-like family is generally
considered to have inhibitory effects (Vallone et al., 2000). All dopamine receptors exert
their effects on cellular functioning through activation of G proteins coupled to the
receptors. The D1-like family act as positive regulators of cyclic AMP by directly
activating adenylyl cyclase, which in turn activates protein kinase A (PKA) (Jackson &
4

Westlind-Danielsson, 1994). PKA phosphorylates different cytoplasmic and nuclear
proteins, leading to alterations in gene expression, cellular metabolism, and various other
modulatory effects on ion channel functioning (Choi et al., 1993). The D2-like family
exerts their inhibitory effects by inhibiting adenylyl cyclase activity (Vallone et al.,
2000).
Dopamine is synthesized by neurons in three discrete brain regions, which project
to four major targets. Dopamine neurons in the ventral tegmental area project to cortical
areas via the mesocortical pathway, and the limbic system via the mesolimbic pathway.
Dopamine neurons in the substantia nigra pars compacta project to the striatum via the
nigrostriatal pathway. Small populations of dopamine neurons in the hypothalamus
project to the pituitary gland via the tuberoinfundibular pathway.
Some of the functions that are interrupted in depression- such as motivation,
psychomotor behavior and feelings of pleasure- are all processes regulated, in part, by
dopamine neurotransmission. Furthermore, not all individuals are responsive to
medications that modulate serotonin and/or norepinephrine neurotransmission. Therefore,
deficits in these dopamine projection streams may play a role in the genesis of depressive
symptoms. The psychomotor symptoms observed in depression may in fact be due to
alterations in dopaminergic neurotransmission to brain regions associated with motor
behavior, as upregulation of D2 receptors have been observed in the basal ganglia and
cerebellum in depressed individuals (D’haenen et al., 1994). Upregulation of the
dopamine reuptake transporter in the striatum have also been observed in depressed
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individuals, which may contribute to low synaptic levels of dopamine (Laasonen-Balk et
al., 1999).
The symptom of anhedonia experienced by people with depression may also be
linked to dopaminergic neurotransmission. In rodent models of depression, such as the
effort expenditure behavioral model, which tests an animal’s willingness to work for a
reward, reductions in dopaminergic neurotransmission to the nucleus accumbens
correlate with reductions in efforts to obtain rewards (Salamone et al., 1999 & Neil et al.,
2002). In this task, reductions in the effort an animal is willing to expend to obtain a
reward is used as an index of anhedonia, or a decrease in the hedonic value of a reward,
which is used as a correlate to the human symptoms of anhedonia. Administration of
tricyclic antidepressants, or the selective serotonin reuptake inhibitor fluoxetine have
been shown to increase dopaminergic neurotransmission to the nucleus accumbens
(Ichikawa & Meltzer 1995). In the chronic mild stress model of depression- where
animals are exposed to mild stressors such as periods of food and water deprivation,
changes in the lighting or temperature conditions in their home cages- decreases in D2
and D3 receptor binding have been observed in the nucleus accumbens, an effect which is
reversed by chronic administration of antidepressant medication (Papp et al., 1994).
Rodents exposed to chronic mild stress conditions also display reductions in the
locomotor and reinforcing effects of the D2 & D3 receptor agonist quinpirole (Wilner et
al., 1992).
In the forced swim test, which is a rodent screening model for novel
antidepressants, animals forced to swim in an inescapable environment rapidly develop
6

an immobile posture. The time an animal spends immobile in used as an indicator of
distress in this task, which can be reduced by administration of D2 & D3 receptor agonists,
dopamine/norepinephrine reuptake inhibitors, and tricyclic antidepressants. These effects
can be blocked by D2 & D3 receptor antagonists (Basso et al., 2005 & Borsini et al.,
1990). Studies designed to test for alterations in dopamine levels in human subjects have
revealed lower cerebrospinal fluid concentrations of homovanillic acid, a dopamine
metabolite, in depressed patients compared to controls. Once dopamine is released it is
metabolized into homovanillic acid via MAO and/or COMT. Lower levels of metabolites
circulating in cerebral spinal fluid are thought to correlate to decreases in
neurotransmitter release. These findings indicate since these depressed individuals have
lower levels of dopamine metabolism occurring as evidenced by their decreased levels of
homovanillic acid, they may also have deficiencies in dopaminergic neurotransmission.
Lower levels of circulating dopamine may therefore be correlated with depression
(Mendels et al., 1972).
The ability of an antidepressant drug to increase dopaminergic neurotransmission
has been shown to correlate with therapeutic efficacy (Rampello et al., 1991). Further
involvement of the dopamine reward system in the genesis of anhedonic symptoms of
depression have been drawn from studies designed to measure the reward responsiveness
of non-medicated depressed patients in response to administration of amphetamine
(Dunlop & Nemeroff, 2007). Non-medicated, severely depressed patients had a
heightened sensitivity to the rewarding effects of amphetamine administration versus
controls. These findings caused investigators to believe that to compensate for a possible
decrease in dopaminergic neurotransmission, up-regulation of dopamine receptors
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coupled with a down-regulation of dopamine transporters may have occurred, resulting in
the elevated sensitivity of depressed subjects to amphetamine (Dunlop & Nemeroff,
2007).
This hypothesis has been supported through the use of functional magnetic
resonance imaging. Following amphetamine administration, non-medicated depressed
individuals displayed greater levels of behavioral responsiveness, and differences in
activity in the ventrolateral prefrontal cortex, orbitofrontal cortex, caudate nucleus and
putamen when compared to healthy controls (Tremblay et al., 2005). Postmortem
findings in depressed individuals who had committed suicide found reductions in
dopamine transporter expression, and increases in D2 & D3 receptors in the central and
basal amygdalar nuclei when compared to controls, while D1 receptor expression did not
differ between depressed individuals and controls (Klimek et al., 2002). The exact role
of the dopaminergic system in the genesis of depressive symptoms remains under
investigation. However, the dopamine plays a pivotal role in non-pathological behaviors
such as attention, reward, pleasure, motivation, and movement. Since the core symptoms
of depression involve dysfunctions in many of these processes, it is likely that the
dopamine system contributes in some way to the pathophysiology of depression.

The role of serotonin in depression
The synapses that serotonin- (5-HT) producing neurons of the raphe system make
with other brain regions may play a role in the genesis of depressive symptoms. For
example, serotonergic neurons originating in the median raphe project to areas of the
8

limbic system, making them likely to modulate anxiety, stress, motivational, and reward
based behaviors. Serotonergic neurons originating in the dorsal raphe nuclei project to
areas of the basal ganglia and the substantia nigra, which provides modulatory input to
the basal ganglia, indicating a potential for modulatory effects on psychomotor behavior
(Frazer & Hensler, 1994). The diversity of serotonergic signaling is immense, as at least
15 serotonin receptor subtypes have been identified (Nichols & Nichols, 2008). The
serotonin receptors can be classified into several families including the 5-HT1 and 5-HT2
receptor families. The other serotonin receptors are designated 5-HT3, 5-HT4 5-HT5, 5HT6 and 5-HT7. All of the serotonin receptors, with the exception of the 5-HT3 receptor,
are metabotropic receptors (Nichols & Nichols, 2008).
The 5-HT1 family are located both pre- and post-synaptically and mediate their
inhibitory effects via coupling of the receptor to a Gi/o protein, which leads to an
inhibition of adenylyl cyclase, preventing the accumulation of cyclic AMP, and thus
reducing activation of the PKA and its intracellular targets (Nichols & Nichols, 2008).
Of the 5-HT1 receptor family, the 5-HT1A and 5-HT1B receptors seem to play the
largest role in the onset of depression. The 5-HT1A receptor is present on serotonergic cell
bodies in the dorsal and median raphe where it mainly functions as a somatodendritic
autoreceptor, decreasing the firing rate of serotonin releasing neurons by activation of
inward rectifying potassium channels and creating sustained levels of hyperpolarization
(Aghajanian et al., 1995). As for the neural targets serotonin neurons project to, including
the frontal cortex, amygdala, hippocampus, septum and entorhinal cortex, 5-HT1A
receptors exist mainly postsynaptically, although this difference in receptor expression
9

may still have a modulatory effect on serotonin release via feedback loops to the raphe
system (Hensler, 2003).
The 5-HT1A receptor seems to play a role in the response to antidepressant drug
administration. Initially, administration of a selective serotonin reuptake inhibitor
increases serotonin concentrations in the raphe nuclei, but due to the inhibitory nature of
the 5-HT1A autoreceptor, the drug initially causes decreases in the firing rate of midbrain
raphe nuclei. After some time however, these receptors are thought to undergo functional
desensitization allowing for a disinhibition of raphe serotonergic neurons (Nichols &
Nichols, 2008).
By administering a 5-HT1A antagonist, it is theorized that the relatively long
latency period for the onset of therapeutic efficacy in response to antidepressant drug
administration can be shortened, a hypothesis which has been supported in animal models
of depression (Artigas, 1993). Mice with a genetic deletion of the serotonin 5-HT1A
receptor also display depressive- and anxiety-like behaviors in a variety of behavioral
assesments including the forced swim test, elevated plus maze, and open field tests
(Ramboz et al., 1998).
The 5-HT1B receptor mimics some of the effects of the 5-HT1A receptor in
response to selective serotonin reuptake inhibitors. The 5-HT1B receptor is selectively
down-regulated in the raphe nuclei following treatment with the selective serotonin
reuptake inhibitor fluoxetine, while expression in areas in the terminal field of serotonin
releasing neurons remains unchanged (Neumaier et al., 1996). Similar to the 5-HT1A
receptor, the 5-HT1B receptor may also undergo functional desensitization in response to
10

chronic antidepressant administration, suggesting the possibility that antagonizing the 5HT1B receptor may also be a potential target to decrease the latency to the onset of
therapeutic effects of antidepressant medications.
The 5-HT2 receptor family also has a few receptor subtypes that are pertinent to
the pathophysiology of depression. The 5-HT2 receptor family are metabotropic receptors
coupled to several different members of the Gq family of G proteins (Nichols & Nichols,
2008). Activation of Gq proteins achieves general stimulatory effects via activation of the
PKC signaling pathway, which gives rise to increased intracellular calcium levels via
modulation of ion channels or release from the endoplasmic reticulum. These effects can
ultimately result in a diverse array of intracellular changes to cells.
Many antidepressant medications target 5-HT2A receptors, particulary in the
prefrontal cortex (Celada et al., 2004). 5-HT2A receptors are highly expressed in the
neocortex, and their actions there are thought to mediate aspects of executive functioning
that are often impaired in people with depression. Many clinically effective
antidepressant medications block the actions mediated by 5-HT2A receptors, and with
chronic treatment, downregulation of 5-HT2A receptors has been observed (Marek et al.,
2003). In the differential reinforcement of low rate responding at 72 second schedules
behavioral model, in which animals must learn to wait a period of 72 seconds between
responses in order to receive rewards, blockade of 5-HT2A receptors in the prefrontal
cortex augments the antidepressant effects of selective serotonin reuptake inhibitors.
These effects are thought to be mediated by postsynaptic 5-HT2A receptors, as the
observed effects did not involve a presynaptic increase in the release of serotonin (Marek
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et al., 2001). The medial prefrontal cortex sends projections to many areas associated
with the different symptoms of depression, such as the nucleus accumbens, the amygdala,
limbic structures, the hypothalamus, and other prefrontal regions. Changes in prefrontal
functioning may, therefore, influence the development of anhedonic symptoms: anxiety
and altered stress responses, mood disturbances and motivational problems, alterations in
endocrine function and changes in hunger, appetite, and sleep behavior. Additionally,
serotonergic modulation of the connections to these brain regions may lead to
impairments in memory and other cognitive functions (Groenewegen & Uylings, 2000).
The 5-HT2C receptor is also of interest in determining the underlying
pathophysiology of depression. 5-HT2C receptors are highly expressed in the amygdala,
and the application of 5-HT2C agonists produces patterns of neuronal activation in the
amygdala, hippocampus and hypothalamus indicative of anxiety behavioral states
(Hackler et al., 2007). Via action at the amygdala and hypothalamus, the 5-HT2C receptor
may be involved in modulation of the hypothalamic-pituitary-adrenal axis, and may play
a role in the elevations in cortisol observed in depressed individuals (Heisler et al., 2007).
Two more noteworthy serotonin receptors may also play a role in the genesis of
depressive symptoms. Both are coupled to the Gs family of G proteins, which have an
overall stimulatory effects on expressing cells by driving cAMP production via
stimulation of adenylyl cyclase, which, in turn, activates the PKA signaling pathway
(Nichols & Nichols, 2008). The 5-HT6 receptor is expressed throughout the striatum,
nucleus accumbens, cortex, olfactory tubercle, hippocampus, thalamus, amygdala,
hypothalamus, and cerebellum (Nichols & Nichols, 2008). The 5-HT6 receptor alters
12

dopaminergic and acetylcholine levels, an effect that has the potential to enhance the
anhedonic and cognitive symptoms seen in depression (Nichols & Nichols, 2008). The 5HT6 receptor may also play a role in the effects of antidepressant medications. While
antagonism of the 5HT6 receptor blocks the antidepressant effects of selective serotonin
reuptake inhibitors, agonists at the 5HT6 receptor have shown promise as antidepressant
agents in animal models (Svenningsson et al., 2007, & Wesolowska et al., 2007).
There is interest in the potential role the serotonin 5-HT7 receptor may play in the
pathophysiology of depression. Although a lack of specific agonists for the receptor have
limited efforts in determining the exact function of this receptor, knockout studies in 5HT7 deficient mice have demonstrated a decrease in immobility in the forced swim test, a
behavioral index which is intended to measure antidepressant activity in humans (Guscott
et al., 2005). Administration of 5-HT7 antagonists also promotes the effects of
antidepressant medications in the forced swim test in wild type mice (Wesolowska et al.,
2007).

The role of norepinephrine in depression
There are three general types of noradrenergic adrenoceptors. β adrenoceptors are
generally stimulatory in nature via coupling to Gs-type G proteins; α1 adrenoceptors are
also stimulatory in nature via coupling to Gq-type G proteins, while α2 adrenoceptors
exert inhibitory effects through their coupling to Gi-type G proteins. α1 adrenoceptors
may play a facilitatory role in serotonergic neurotransmission, as application of α1
13

antagonists cause a decrease in serotoninergic neuronal firing in the raphe nuclei
(Barabaran & Aghajanian, 1980). Presynaptically, α2 receptors serve mainly to modulate
the release of both serotonin and norepinephrine. As either autoreceptors, when acting on
adrenergic neurons, or heteroreceptors- receptors that modulate the function of a cell via
neurotransmitter released from adjacent neurons- when acting on serotonergic neurons.
Consistent with the adaptations observed in receptor sensitivity and distribution
studies for the other monoamine neurotransmitters in response to chronic antidepressant
administration, and in animal models of sustained depressive symptoms, adaptations also
occur in the noradrenergic system. Desensitization and downregulation of expression of β
adrenoceptors has been observed following chronic administration of the tricyclic
antidepressant desipramine, and also following electroconvulsive therapy (Heal et al.,
1989). Upregulation of β adrenoceptors has also been observed in depressed individuals,
and a decrease in β adrenoceptor expression is considered a clinical marker for
antidepressant drug efficacy (Leonard, 1997). Changes in α1 adrenoceptor expression
have also been reported, but in contrast to β adrenoceptors, α1 adrenoceptors seem to be
up-regulated in response to antidepressant drug administration. Results of radioligand
binding assays have demonstrated an increase in α1 binding following repeated
administration of the tetracyclic antidepressant mirtazapine, leading investigators to
believe that increases in the responsiveness and number of α1 adrenoceptors may have
taken place (Rogoz, et al., 2002). These results have been duplicated using the
norepinephrine reuptake inhibitor reboxetine (Rogoz & Kolasiewicz,, 2001).
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α2 adrenoceptors are thought to undergo a functional desensitization in response
to chronic antidepressant administration, a process that may account for the latency in the
onset of therapeutic efficacy in antidepressant drugs. As heteroreceptors on serotonergic
neurons, α2 adrenoceptors are thought to decrease the release of serotonin. As
autoreceptors, α2 adrenoceptors decrease the release of norepinephrine. Thus, by
modifying the receptors expression or efficacy, increases in adrenergic and serotonergic
neurotransmission may be achieved (Dennis et al., 1987).
Evidence for this desensitization hypothesis is drawn from studies using a
combination of chronic antidepressant treatment combined with α2 agonists to measure
decreases in the behavioral effects of α2 agonism. Following 3-4 weeks of treatment with
the tricyclic antidepressant desipramine, decreases in the behavioral responses to α2
agonism, including antinociceptive effects, and durations in the loss of righting reflexes
were observed. These results were reversible by administration of α1 antagonists (Guo et
al., 1998), and indicate that α1 receptors may play a modulatory role in antidepressant
induced hyporesponsiveness to α2 agonists.
Further evidence for the desensitization hypothesis has come from findings that
norepinephrine concentrations are significantly elevated following chronic treatment with
desipramine, an effect which lasts following cessation of drug treatment. This stimulatory
effect on norepinephrine release was further potentiated following a challenge
administration of desipramine 48 hours after drug treatment had ceased (Sachetti et al.,
2001). To test whether these effects were specific to the α2 receptor, the α2 agonist
clonidine was administered and resulted in decreases in noradrenergic neurotransmission
15

in control animals with no change observed in desipramine-treated animals (Sachetti et
al., 2001). These findings indicate that the facilitatory effects desipramine exerts on
noradrenergic neurotransmission may be due to a lasting desensitization specifically at α2
adrenergic receptors.
Changes in the expression of α2 receptors have been demonstrated in humans as
well. Treatment with tricyclic antidepressant drugs attenuates the hypotension, sedation,
and reduction in norepinephrine turnover in response to clonidine administration in
humans as well as animals (Charney 1981 & 1983), an effect that did not occur following
treatment with the tetracyclic antidepressant mianserin (Charney et al., 1984).
Furthermore, a review of postmortem studies of suicide victims not receiving
antidepressant medication found increases in α2 expression in the prefrontal cortex of 3140% of individuals observed (Garcia-Sevilla et al., 1999). These findings, taken together,
may indicate that while in some instances α2 desensitization may play a role in the
efficacy of antidepressant medications such as the tricyclics, in other antidepressant
medications like the tetracyclics, it may not be necessary to achieve therapeutic efficacy.
These results may be further interpreted as an indication of the diversity in the
pathophysiology of depression, which is exemplified by the fact that not everyone reacts
the same way to certain classes of antidepressant medication. Medications with one
mechanism of action (inhibition of serotonin reuptake) may produce great improvements
in symptoms in one patient, while providing no relief whatsoever in another.
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Pharmacotherapies for depression
Most of the currently available medications used in the treatment of depression in
humans target one or more of the brain’s monoaminergic neurotransmitter systems.
Typically, these medications aim to increase levels of monoamines in the brain. A variety
of medications with varying mechanisms of action are currently available to physicians to
assist patients in the management of depressive symptoms. These include: (1) the
selective serotonin reuptake inhibitors, which increase the availability of serotonin
synaptically via blockade of serotonin reuptake transporters, (2) mixed
serotonin/norepinephrine reuptake inhibitors, which increase the availability of serotonin
and norepinephrine via blockade of their reuptake, (3) monoamine oxidase inhibitors,
which prevent the degradation of monoamines by monoamine oxidase, (4)
dopamine/norepinephrine reuptake inhibitors, which increase synaptic concentrations of
dopamine and norepinephrine via blockade of dopamine and norepinephrine reuptake, (5)
and the tricyclic antidepressants, which act as serotonin/norepinephrine reuptake
inhibitors and antagonists at a range of receptors.
The tricyclics were among the first available treatment strategies for depression,
with imipramine being the first clinically available tricyclic antidepressant in the early
1950’s (Lopez-Munoz et al., 2009). There is some variation among the specific affinities
between tricyclic antidepressants, but they were originally developed as antihistaminergic compounds and most commonly act as antagonists at the histamine H1
receptor (Lopez-Munoz, 2004). The tricyclic imipramine acts as a potent inhibitor of
serotonin reuptake, an inhibitor of norepinephrine reuptake, and as an antagonist at H1
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receptors, α1 adrenoceptors, cholinergic muscarinic receptors, and 5-HT2A receptors
(Gillman, 2007). This binding profile may account for both the therapeutic efficacy of
imipramine and some of the unpleasant side effects associated with the use of tricyclic
antidepressants. For instance, although H1 antagonism may play a role in the therapeutic
efficacy of imipramine, it may also contribute to the sedation and weight gain observed
following treatment (Kroeze et al., 2003). Antagonism at the 5-HT2A receptor has been
hypothesized to play a role in improving the observed dysfunctions in sleep observed in
depressed individuals (Thase, 2006). Antagonism at the α1 receptor is presumed to play
a role in the development of postural hypotension developed following administration of
tricyclics like imipramine (Smith, 2001). The development of anti-muscarinic side
effects like dry mouth, blurred vision, urinary retention, tachycardia, constipation and
impairments in memory arise from antagonism of muscarinic receptors (Gillman, 2007).
These anti-muscarinic properties are especially worrisome for the elderly, where
therapeutic doses have been noted to produce delirium (Gillman, 2007).
In addition to these adverse effects, responsiveness to antidepressant therapy
varies on an individual basis. These variations depend largely on the severity of
symptoms. Patients with mild to moderate depression seem to respond less favorably to
antidepressant treatment (Zimmerman et al., 2002). Patient compliance may also play a
role in the ineffectiveness of antidepressant medications. Due to the long onset of action
of these medications and the presence of adverse side effects at therapeutic dosages, it
has been estimated that as few as 30% of patients take their medications as prescribed
(Weich et al., 2007 & Bockting et al., 2008). The combination of adverse effects and the
long latency (10-14 weeks) to the onset of therapeutic actions seen in antidepressant
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medications highlight the need for alternative mechanisms of action for the treatment of
depression.

The neurotensin system
Neurotensin is a neuropeptide signaling molecule first isolated in the bovine
hypothalamus in 1973 by Robert Carraway and Susan E. Leeman. The full peptide
molecule consists of 13 amino acid residues, of which segments 8-13 are linked to the
biological effects of neurotensin (Lambert et al., 1995). There are currently three
identified neurotensin NTS receptors within the central nervous system, designated the
NTS1, NTS2 and NTS3 receptors.
The three receptors differ significantly in their affinities for the neurotensin
peptide. The NTS1 receptor binds neurotensin with high affinity and is insensitive to the
H1 receptor antagonist levocabastine (Tanaka, et al., 1990), while the NTS2 receptor has
low affinity for neurotensin itself, but binds levocabastine with high affinity (Vincent et
al., 1999). Neurotensin acts as an agonist at the NTS1 receptor, and upon binding to the
NTS1 receptor, neurotensin causes a coupling of the agonist bound receptor to a Gq-type
G-protein, and subsequent activation of an associated signal cascade. It is unclear
precisely what action neurotensin binding to the NTS2 receptor produces, as speciesspecific differences exist in the post-binding events associated with the NTS2 receptor
(Vincent et al., 1999). Clones of human NTS2 receptors transfected into Chinese hamster
ovaries or Xenopus oocytes are antagonized by application of neurotensin or
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levocabastine, while both of these compounds act as agonists at the NTS2 receptor in
mouse or rat tissue preparations (Vincent et al., 1999).
The NTS1 & NTS2 receptors are both G-protein coupled receptors, while the NTS3
receptor is unique, as it is not coupled to a G-protein. The neurotensin 3 receptor has a
low affinity for neurotensin and shares a 100% amino acid homology with the
gp95/sortilin complex previously isolated from human tissue (Mazella et al., 1998). The
physiological relevance of this receptor is unclear, as no signaling mechanisms have been
linked to this binding site (Tyler-McMahon, 2000).
The neurotensin peptide plays a role in a diverse set of functions in both the
central and peripheral nervous system. In the periphery, neurotensin acts as a paracrine
and endocrine peptide with notable effects in the gastrointestinal tract, cardiovascular
system, and in the proliferation of normal and cancerous cell growth (Tyler-McMahon et
al., 2000). In the central nervous system, administration of neurotensin produces
hypothermia, reduces nociception, and has modulatory effects on monoaminergic
neurotransmission and effects on endocrine transmission, stimulating the release of
corticotrophin releasing factor, galanin, enkephalin, cholecystokinin and growth
hormone–releasing hormone (Tyler-McMahon, 2000). However, due to the large size of
the full peptide, and the fact that it is degraded rapidly via protease metabolism following
systemic administration, the full peptide form of neurotensin is does not cross the blood
brain barrier. However, only the final 6 amino acids (8-13) of the neurotensin peptide are
needed for the full physiological effects of the neurotensin peptide, a finding which has
allowed for the development of brain penetrant analogs of the 8-13 segment of the
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neurotensin peptide (Tyler-McMahon, 2000). NTS1 agonists produce all the
physiological and behavioral responses associated with neurotensinergic
neurotransmission. Therefore, until further knowledge can be gained regarding the
biological relevance of the NTS2 receptor within and across species, the effects of
manipulating the neurotensin system are assumed to be mediated by the NTS1 receptor.

The NTS1 receptor
As the NTS1 receptor is the only neurotensin receptor that binds neurotensin with
high affinity, it is assumed to play the most important role in the physiological actions of
the neurotensin peptide. NTS1 activation mediates its excitatory effects following agonist
binding through a preferential coupling to Gq/11 G-proteins, leading to activation of the
protein kinase C pathway through activation of phospholipase C and phosphatidylinositol
4,5-biphosphate with inositol triphosphate and Ca+2 acting as second messengers
(Richard et al., 2001). The agonist bound NTS1 receptor may also bind to Gs G-proteins
in certain circumstances, as increases in cAMP production have been found following
agonist application in Chinese hamster ovary tissue preparations (Yamada et al., 1994).
Activation of the NTS1 receptors in these tissue preparations also results in a prolonged
activation of mitogen-activated protein kinases and the growth associated gene krox-24.
These effects were eliminated following application of the NTS1 antagonist SR 48692
(Poinot-Chazel, et al., 1996).
Once an agonist binds to the NTS1 receptor several proposed mechanisms mediate
the physiological effects of the agonist-bound receptor. First, upon binding internalization
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of the agonist/receptor complex may function as a transcriptional regulator. Second,
allosteric interactions between the NTS1 receptor and the D2 receptor may occur, and
binding of an agonist to the NTS1 receptor may lower the affinity of the D2 receptor to
bind ligands. Third, NTS1 receptor activation may alter neuronal excitability, and
following agonist binding may alter second messenger signal cascades and ion channel
functioning through it’s coupling to G-Proteins (Binder et al., 2001, St-Gelais et al.,
2006).

Distribution of the NTS1 receptor
The NTS1 receptor is widely distributed throughout many areas of the brain. A
comprehensive mapping of the location of NTS1 receptors in the rat brain using
immunohistochemical labeling comparatively verified with application of 125-Iodine
labeled neurotensin was performed by Boudin et al. (1996). In the telencephalon, NTS1
receptor immunoreactivity was discovered on pyramidal cell bodies within layers II-III &
V, and on dendrites in layer IV in the frontal and parietal cortices. In the anterior
cingulate, endopiriform and insular cortices, NTS1 receptors were detected mainly on
axon terminals within layer IV. In the perirhinal cortex, labeling was present on axon
terminals in layers I-III & VI, with punctate labeling present on cell bodies in layers IV
&V. Entorhinal cortical labeling displayed a weak and scattered immunoreactive signal
across cell bodies. In the retrosplenial cortex labeling occurred primarily in terminal
regions in layer I, while layers II & III displayed labeling on both cell bodies and axon
terminals. Within the caudate-putamen, NTS1 receptors were identified on axon
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terminals and cell bodies, and on cell bodies and axons within the nucleus accumbens.
Within the olfactory tubercle, labeling was concentrated on dendrites and cell bodies
within the granule cells of the islands of Calleja. In the basal forebrain NTS1 receptors
were located on cell bodies within the medial septum, diagonal band of Broca, and were
densely labeled on dendrites and cell bodies within the magnocellular preoptic nucleus,
substantia innominate, and globus pallidus. Axonal labeling with sparse labeling of cell
bodies was present within the lateral septum and the bed nucleus of the stria terminalis.
Labeling within the amygdala differed between the substructures therein, with cell
bodies, dendrites and axon terminals present on the posterior cortical nucleus, neuropil
labeling within the basomedial and lateral amygdalar nuclei, and axonal labeling within
the central nucleus. In the hippocampus, NTS1 receptors were found in the presubiculum,
parasubiculum, and subiculum on cell bodies, dendrites, and axon terminals. In the CA1,
CA2, and CA3 regions, as well as the pyramidal and granule cell layers labeling was
detected on cell bodies. Within the diencephalon, several thalamic nuclei also displayed
an immunoreactive signal. Labeling was strongest on cell bodies within the anterior
dorsal thalamic nucleus, though labeling was also present on beaded fibers within the
paraventricular thalamic nucleus, cell bodies and neuropil in the reticular nucleus, and
cell bodies and dendrites within the nucleus of the optic tract. In the hypothalamus,
densely labeled axon terminals were identified within the medial and lateral nuclei, and
densely labeled cell bodies and processes were identified in the suprachiasmatic nucleus.
In the periventricular nucleus, the parvocellular part of the anterior paraventricular
nucleus, as well as the lateral mammillary nucleus, NTS1 receptors were identified on
axons. In the zona incerta, NTS1 receptors were located on cell bodies in the ventral
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portion, while dorsally they were present mainly on dendrites. Scattered labeling was also
observed across the medial and lateral habenula. In the mesencephalon, densely labeled
cell bodies and dendrites were identified in the substantia nigra pars compacta, ventral
tegmental area and other associated midline structures including the interfascicular
nucleus and the nucleus of the raphe linearis caudalis. Immunoreactivity was also
detected on cell bodies within the substantia nigra pars reticulata and pars lateralis. NTS1
receptors were also detected on cell bodies and dendrites within the periaqueductal grey,
dorsal raphe, median raphe, and laterodorsal tegmental nuclei. Axonal labeling was also
identified in the laterodorsal tegmentum and locus coeruleus. Within the brainstem,
immunoreactivity was observed on cell bodies and neuropil throughout the pontine
nuclei, with heavily labeled cell bodies identified within the reticulotegmental nucleus,
and densely labeled processes around the medial lemniscus and medical longitudinal
fasciculus. In the medulla, NTS1 receptors were detected on cell bodies in the medial
vestibular, dorsal cochlear nuclei, and the parvocellular reticular formation. Intense
signals were detected on cell bodies and dendrites within the nucleus raphe pallidus, the
inferior olivary nucleus, and the paragigantocellular nucleus. Caudally, NTS1 receptors
were detected on cell bodies and dendrites within the dorsal motor nucleus of the vagus,
and on axon terminals within the nucleus of the solitary tract. Cell bodies and dendrites
within the external cuneate and lateral reticular nucleus, as well as motor neurons in the
hypoglossal nerve nucleus also displayed immunoreactivity (Boudin et al., 1996).
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Effects of neurotensin on dopaminergic neurotransmission
Many studies have been performed to examine the influence application of
agonists at the NTS1 receptor have on dopaminergic neurotransmission. These have
included application of agonists into the ventral tegmental area, the origin of the
mesocortical and mesolimbic dopamine streams, the substantia nigra pars compacta, the
origin of the nigrostriatal dopamine tract, as well as the terminal fields of these dopamine
projection pathways.
Application of either the full peptide form of neurotensin or two analogs, the 8-13
fragment of the neurotensin peptide, or [D-Tyr-11]neurotensin directly into the ventral
tegmental area produces differential effects on dopamine efflux in the terminal regions of
the mesocortical/mesolimbic dopamine streams (Sotty et al., 2000). Injection of all three
compounds at concentrations of 10−3 M produced elevations in extracellular dopamine
levels in the prefrontal cortex as measured by differential normal pulse voltammetry or
differential pulse amperometry, though the elevations in dopamine produced by [D-Tyr11]neurotensin lasted longer (Sotty et al., 2000). Injections of 10−5 M concentrations of
neurotensin and (8-13) neurotensin produced results similar to those produced by 10−3 M
concentrations of these two compounds, while 10−5 M concentrations of [D-Tyr11]neurotensin did not significantly alter dopamine efflux into the prefrontal cortex.
Similar patterns of activity were found in the nucleus accumbens, where all three
compounds produced elevations in extracellular dopamine levels at concentrations of 10−
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M and 10−5 M, with [D-Tyr-11]neurotensin producing more prolonged increases in

dopamine levels (Sotty at al., 2000).
Systemic administration of NT69L, an analog of the 8-13 amino acid sequence of
the neurotensin peptide also influences dopaminergic neurotransmission in the prefrontal
cortex and nucleus accumbens as measured by microdialysis (Prus et al., 2007). At doses
of 1.0 and 3.0 mg/kg, NT69L produced significant increases in dopamine levels in the
prefrontal cortex, while only the 1.0 mg/kg dose of NT69L produced significant increases
in dopamine levels within the nucleus accumbens (Prus et al., 2007).
Stimulation of NTS1 receptors in the prefrontal cortex may have modulatory
effects on feedback pathways transmitting from the prefrontal cortex back to midbrain
dopamine producing nuclei. Microinjection of the full peptide form of neurotensin or the
8-13 fragment of the neurotensin peptide into the rat prefrontal cortex produces increased
firing rates in ventral tegmental dopamine-producing neurons, while microinjection of the
1-8 fragment of the neurotensin peptide does not (Fatigati et al., 2000). Injection of
neurotensin into the rat prefrontal cortex also facilitates dopaminergic release in the
prefrontal cortex, an effect that can be antagonized by application of the NTS1 receptor
antagonist SR 48692 (Petkova-Kirova et al., 2008).
Neurotensin also plays a modulatory role on dopaminergic functioning in the
substantia nigra pars compacta. Microinjections of neurotensin into the substantia nigra
pars compacta produces elevated levels of dopamine efflux into the rodent basal ganglia,
an effect which has been demonstrated to last for as long as 20 hours (Napier et al.,
1985).
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Beaucse injection of neurotensin into the origins and terminal fields of the
midbrain dopamine streams can produce elevated dopamine levels, the facilitatory effects
of neurotensin on dopamine release may be due to mixed presynaptic/somatodendritic
stimulatory effects depending on the locus of action. These effects also seem to be
dependent on NTS1 receptor activation, as application of selective NTS1 receptor
antagonists prevents these effects. However, the full neurotensin peptide is a large,
rapidly degraded, brain impenetrable peptide, which makes it unsuitable for central
nervous system activity when administered systemically. Fortunately, analogs of the
biologically active 8-13 fragment of the neurotensin peptide are systemically
administrable, and have demonstrated efficacy in the facilitation of dopamine release.

Effects of neurotensin on serotonergic neurotransmission
Although it has not received quite as much attention as the dopaminergic system,
the literature suggests that neurotensin also plays a facilitatory role in serotoninergic
neurotransmission. In vitro, application of the full neurotensin peptide, and the 8-13
fragment of the neurotensin peptide increases the firing rate of dorsal raphe serotonergic
neurons in a concentration dependent manner, while application of the selective NTS1
receptor antagonist SR 48692 blocks these effects (Jolas & Aghajanian, 1996).
Application of the 1-8 fragment of the neurotensin in the same set of experiments did not
induce increases in firing rates; more evidence supporting the efficacy of analogs of the
neurotensin peptide.
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In the raphe magnus, application of neurotensin to in vitro tissue preparations also
induced depolarization of serotonergic neurons and increased the generation of action
potentials (Li et al., 2001). Further experiments were carried out to determine the
mechanisms by which neurotensin exerted these effects. Application of anti-Gq/11
antiserum prevented the excitatory effects neurotensin had on raphe magnus serotonin
neurons. Application of the IP3 inhibitor heparin, and BAPTA, a Ca+2 chelator also
impaired the excitatory effects exhibited by neurotensin (Li et al., 2001). These
experiments provide further support for the Gq/11, IP3, Ca+2 signal cascade in mediating
the excitatory effects of neurotensin.
Application of both the full neurotensin peptide and the 8-13 fragment induce
increases in prefrontal cortical serotonin release in vitro (Heaulme, M., 1998), effects that
are antagonized by application of the NTS1 receptor antagonist SR 48692. In vivo,
microinjection of neurotensin into the prefrontal cortex of rats also induces sustained
elevations in serotonin release, an effect that is also inhibited by application of SR 46892
(Petkova-Kirova et al., 2008).
Though much of the research on the neurochemical modulations induced by
neurotensin has focused on dopamine, the serotonergic system is also affected. Further
study into the modulatory role the neurotensin system plays on serotonergic
neurotransmission could further validate the use of neurotensin analogs in the treatment
of disorders involving imbalances in serotonergic neurotransmission, including
depression.
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Effects of neurotensin on noradrenergic neurotransmission
If research into the role neurotensin plays in serotonergic neurotransmission is
lacking, the role neurotensin plays in noradrenergic neurotransmission is even scarcer.
However, the minimal evidence gathered into the modulatory role neurotensin plays on
noradrenaline in the central nervous system indicates there may be interactions at play
worth further study. In one such study, rats trained to self-administer nicotine were forced
to undergo a withdrawal period. During this withdrawal period, animals that previously
had received saline/nicotine treatment displayed significantly higher concentrations of
noradrenaline within the striatum than animals that received neurotensin/nicotine
treatment (Boules et al., 2011). These results may indicate that neurotensin administration
could provide protective benefits against increased noradrenergic neurotransmission in
response to the stress induced by nicotine withdrawal.

Evidence from animal models of depression
Neurotensin analog drugs have been most thoroughly researched as therapeutic
agents to treat schizophrenia. The NTS1 receptor agonist PD149163 has displayed
antipsychotic effects in variety of animal models of schizophrenia such prepulse
inhibition (Feifel et al., 2011), and conditioned avoidance tasks (Holly et al., 2011),
where it displays antipsychotic-like effects without producing catalepsy.
In addition to its role in the treatment of schizophrenia, the neurotensin system
may also represent a novel target for the treatment of depression. Animals with a genetic
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deletion of the NTS1 receptor display several anxiety- and depression-like behaviors.
Deletion of the NTS1 receptor results in alterations in sleep architecture and abnormal
recovery from periods of sleep deprivation (Fitzpatrick et al., 2012), which may correlate
with sleep disturbances seen in human patients with depression. In the tail suspension
test, an animal behavioral model of depression, NTS1 receptor knockout mice display
greater levels of immobility than their wild type counter parts. In another experiment
using the same animals, NTS1 receptor knockout mice displayed greater levels of anxietylike behavior in an open field test, spending more time in the corners of the apparatus and
less time in the center, indicative of an enhancement of thigmotaxia. The NTS1 agonist
PD149163 may also possess anxiolytic effects, as acute administration of PD149163
reduces conditioned foot shock-induced ultrasonic vocalizations (Prus et al., 2014).

Neurotensin in the forced swim test
The measurement of depression-related behaviors in animals is a difficult task, as
animals are unable to directly report feelings of sadness or despair. However, several
screening models do exist in which drugs that produce antidepressant effects in human
beings exert a consistent effect on animal behavior. One such test is the forced swim test.
The forced swim test is a commonly used screening model for novel
antidepressant medications in which animals are placed in a cylinder partially filled with
water from which there is no escape. After some time, the animals cease swimming and
instead adopt a passive, immobile posture characterized by the animal only emitting
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movements necessary to stay afloat. Drugs that have antidepressant efficacy in humans
reliably decrease the amount of time that animals spend in this immobile posture, while
increasing escape, exploratory, or general swimming behaviors. However, drugs that
produce stimulant like effects such as caffeine, nicotine, or amphetamine produce a false
positive in the forced swim test as they decrease immobility behaviors while not
possessing antidepressant efficacy (Castagne et al., 2009). For this reason, a locomotor
assessment is generally performed in conjunction with the forced swim test to ensure that
any reductions in immobility observed are not due to a general stimulatory effect on
locomotor behavior. If a drug produces a reduction in immobility in the forced swim test
without increasing locomotor behavior in the locomotor assessment, then the test
substance may produce antidepressant effects in humans.
Very few studies to date have explored the role of the neurotensin system on
animal behavior in the forced swim test. One study reported an increase in immobility
behavior in mice with a genetic deletion of the NTS1 receptor (Li et al., 2010), while
another did not find significant differences between wild type mice and NTS1 receptor
knockout mice (Fitzpatrick et al., 2012). Although the levels of immobility between the
two groups in the second study did not reach statistical significance, the authors did
report a trend in their data toward greater levels of immobility in NTS1 receptor deficient
mice. Microinjection of the full peptide form of neurotensin directly into the ventral
tegmental area resulted in antidepressant-like effects in rats during the forced swim test
(Cervo et al., 1992), indicating that in normal animals, exogenous stimulation of NTS1
receptors may exert antidepressant effects. What is unknown is whether systemically
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administrable neurotensin analog drugs like PD149163 will also produce antidepressant
effects in the forced swim test.
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RATIONALE

Due to the large number of patients that do not respond to antidepressant
treatment and the long latency to the onset of therapeutic effects in existing options,
novel mechanisms for the treatment of depression are needed. According to the
monoaminergic theory of depression, imbalances in one or more of the brains
monoamine neurotransmitter systems may lead to the genesis of depressive symptoms.
Most of the currently available antidepressant medications aim to increase the synaptic
availability of monoamines by a variety of mechanisms such as preventing their reuptake
or metabolism. Neurotensin is an endogenous neuropeptide that has modulatory
influences on monoaminergic neurotransmission in areas of the brain involved in
depression. The neurotensin system has been implicated in a wide variety of psychiatric
disorders including schizophrenia, anxiety, and depression. Agonists for the NTS1
receptor have displayed therapeutic potential in a variety of animal models of psychiatric
disorders but what is unclear is whether NTS1 agonists exhibit antidepressant properties
in animal models of depression.
The current study aimed to evaluate the effects of the NTS1 agonist PD149163 in
the forced swim test, a rodent screening model for putative antidepressant medications.
The effects of PD149163 and the tricyclic antidepressant imipramine were compared to
saline control animals to determine if these compounds may possess antidepressant
properties in human patients. To ensure that any alterations in swimming behavior
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observed in the forced swim test were not due to alterations in motor behavior alone a
locomotor assessment was also performed.

34

METHODS

Experiment 1
Subjects
Forty-eight male C57/Bl6 mice (Charles River Laboratories, Portage, MI) were
used in this study. All animals were approximately 2 months of age and weighed between
23-28 grams at the beginning of these procedures. Mice were group housed in a
temperature-controlled room (22±3°C) with a 12-hour light/dark cycle and were
provided free access to food and water in their home cages. The housing and
experimental procedures were approved by the Northern Michigan University
Institutional Animal Care and Use Committee (#227).

Apparatus
The forced swim test apparatus was a 2L glass beaker (19 cm height, 14 cm
diameter) filled with 12 cm of water warmed to a temperature of 23 °C. Twelve cm
of water was of sufficient height so that at no point during testing could any part of
the animals body touch the bottom of the beaker. Three animals were run
simultaneously each in their own individual beaker with cardboard dividers
positioned on the left and right sides of each beaker so the animal could not see the
adjacent testing apparatus, or the surrounding experimental room. 8x11” sheets of
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white computer paper were taped to the cardboard dividers and the background wall
to provide contrast to the animals black color.

Drugs
Imipramine hydrochloride was obtained from Sigma-Aldrich (St. Louis,
MO), and PD149163 was obtained from RTI International (Research Triangle
Park, NC). Imipramine and PD149163 were dissolved in 0.9% saline and
administered at doses of 1.0 mg.kg or 10.0mg/kg, and 0.1 mg/kg or 1.0 mg/kg
respectively. Imipramine, PD149163 and saline were administered 30 minutes
prior to experimental procedures via intraperitoneal injection at a volume of 10
mL/kg. All of the drugs were in salt form.

Behavioral procedures
The experimental procedures began one month after the animals arrived
from the breeder. Day one of the procedures consisted of acclimation to the
testing environment for one hour, followed by the forced swim test procedure.
One week after the forced swim test, the locomotor assessment occurred.
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Forced Swim Test
The forced swim test procedures were similar to those described by
Castagne, Moser, and Porsolt (2009). On the first day of testing, mice were
allowed to acclimate to the environment of the experimental room for 1 hour in
their home cages. Testing sessions lasted a total of 360 seconds and upon
completion of the session animals were placed in a cage lined with paper towels
positioned next to a space heater to dry and warm the animals. To minimize distress,
animals were not manually dried by the experimenters, but instead were allowed to
remain in the paper towel lined cages until sufficiently dry before being returned to
their home cages. According to standard scoring methods for this procedure
(Castagne et al., 2009), immobility time is typically only scored in the final 240
seconds of the trial sessions as animals usually display very little immobility in the
first 120 seconds (Castagne et al., 2009). For the purposes of this study, animal

behavior was recorded for the entire 360 seconds of the testing session, and
behavior from the first two minutes of the testing session was scored and
analyzed separately from behavior in the final four minutes of the testing session.
Mice were randomly assigned to a drug treatment group and received a single
injection of imipramine (1.0 mg/kg or 10.0 mg/kg), PD149163 (0.1 mg/kg or 1.0
mg/kg) or saline 30 minutes prior to the testing session. Immobility was defined
as a lack of all movement except those movements necessary to keep the animals
head above the water. Testing sessions were recorded on video and the total
duration of immobility and the latency to the first episode of immobility were
scored by an observer blind to the experimental conditions. A reduction in time
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spent immobile and increased latencies to the first episode of immobility were
used as indices of antidepressant efficacy.

Locomotor assessment
To rule out non-specific motor effects as a causal factor for any observed
differences in immobility behavior between groups a locomotor assessment was
performed one week following the forced swim test procedure. The locomotor
assessment was carried out in the same room as the forced swim test and all
animals received the same test substance and dose that were given before the
forced swim test. Animals received the test substance 30 minutes prior to being
placed in the locomotor apparatus. Testing sessions lasted for 20 minutes, and
the total distance traveled was calculated using Noldus Ethovision XT 7.0
software (Noldus Information Technology, Leesburg, VA).

Apparatus
The locomotor apparatus was a wooden box with four separate identical
compartments measuring 45.72 cm long x 45.72 cm wide and 27 cm tall. The
floor and side walls were painted white in color to provide contrast to the animals
black color. Animals were tested three at a time each in their own individual
compartment of the apparatus.
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Statistical analysis
The dependent variables measured for the forced swim test were total time
spent immobile in the first two minutes, and the final four minutes of the testing
session, and the latency to the first episode of immobility. The dependent variable
measured for the locomotor analysis was total distance traveled. A one-way
between groups analysis of variance was used to analyze the effects of each drug
(doses and saline) on each measure. Any statistically significant differences were
further analyzed using a Dunnet’s post-hoc analysis to determine which
treatment groups differed from saline control groups. Also, an independent
samples t-tests was performed to determine if the measures taken from the
control animals for imipramine differed from the control animals for PD149163.
All analyses were conducted using GraphPad Prism for Windows version 6.0
(GraphPad Software, La Jolla, CA).
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RESULTS

Forced Swim Test	
  
Time spent immobile: final 4 minutes
Figure 1 represents the mean for the total time spent immobile in the final four
minutes of the testing session for imipramine- and saline- treated mice. Administration of
imipramine significantly changed the total time spent immobile F(2,21)=7.014, p<0.01. A
significant decrease in the total time spent immobile was found at the 10.0 mg/kg dose of
imipramine in comparison to saline.
Figure 2 represents the mean for the total time spent immobile in the final four
minutes of the testing session for PD149163- and saline- treated mice. Administration of
PD149163 significantly altered the total time spent immobile F(2,21)=7.505, p<0.01,
which was due to a significant decrease in the total time spent immobile at both the
0.1mg/kg and the 1.0 mg/kg dose compared to saline.
Figure 3 represents the mean for the total time spent immobile in the last four
minutes of the testing session for the imipramine-paired control animals versus the
PD14916-paired control animals. The average time spent immobile between the 2 groups
was not significantly different t(14)=1.689, p>0.05.
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Time spent immobile: first two minutes
Figure 4 represents the mean for the total time spent immobile in the first 2
minutes of the testing session for imipramine- and saline- treated mice. Administration of
imipramine significantly affected the total time spent immobile F(2,21)=13.18, p<0.001,
due to a significant reduction in the time spent immobile at both the 1.0 mg/kg and the
10.0 mg/kg doses in comparison to saline.
Figure 5 represents the mean for the total time spent immobile in the first 2
minutes of the testing session for PD149163- and saline- treated mice. Administration of
PD149163 significantly changed the total time spent immobile F(2,21)=5.108, p<0.05,
due to a significant decreased the total time spent immobile at the 0.1 dose compared to
saline.
Figure 6 represents the mean for the total time spent immobile in the first 2
minutes of the testing session for the imipramine-paired versus PD149163-paired control
animals. Immobility times for the two groups were not significantly different
t(14)=0.265, p>0.05.
Latency to the first episode of immobility
Figure 7 represents the mean latency to the first episode of immobility for the
imipramine- and saline-treated mice. Administration of imipramine significantly altered
the latency to the first episode of immobility F(2,21)=6.939, p<0.01, due to a significant
increase in the latency at the 10.0 mg/kg dose versus saline.
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Figure 8 represents the mean latency to the first episode of immobility for the
PD149163- and saline- treated mice. PD149163 treated animals did not significantly
differ from their saline control counterparts F(2,21)=2.887, p>0.05.
Figure 9 represents the mean latency to the first episode of immobility for
imipramine-paired and PD149163-paired control animals. The mean latencies for the two
groups were not significantly different t(14)=0.863, p>0.05.

Locomotor Assessment
Total distance traveled
Figure 10 represents the mean for the total distance traveled during the open field
test for imipramine- and saline-treated mice. Administration of imipramine significantly
affected the total distance traveled F(2,21)=14.830, p<0.001, which was due to a
significant decrease in the total distance traveled at the 10.0 mg/kg dose of imipramine
compared to saline.
Figure 11 represents the mean for the total distance traveled during the open field
test for PD149163- and saline-treated mice. Administration of PD149163 significantly
altered the total distance traveled F(2,21)=4.733, p<0.05, due to a significant reduction in
the distance traveled at the 1.0 mg/kg dose in comparison to saline.
Figure 12 represents the mean for the total distance traveled for imipraminepaired and PD149163-paired control animals. The total distance traveled for the two
groups did not significantly differ t(14)=0.5033, p>0.05.
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All figures represent the mean plus the standard error of the mean.
Figure 1: Imipramine: Immobility in the Final 4 Minutes

Figure 1 represents the mean for the time spent immobile in the final four minutes of the
testing session for imipramine- and saline- treated mice. Treatment with 1.0 mg/kg of
imipramine had no significant effect when compared to saline control animals (p>0.05).
Treatment with 10.0 mg/kg of imipramine significantly reduced the time spent immobile
(p<0.01) compared to saline-treated animals.
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Figure 2: PD149163: Immobility in the Final 4 Minutes

Figure	
  2	
  represents	
  the	
  mean	
  for	
  the	
  total	
  time	
  spent	
  immobile	
  in	
  the	
  final	
  4	
  
minutes	
  of	
  the	
  testing	
  session	
  for	
  PD149163-‐	
  and	
  saline-‐	
  treated	
  mice.	
  Treatment	
  
with	
  0.1	
  mg/kg	
  of	
  PD149163	
  produced	
  a	
  significant	
  reduction	
  in	
  the	
  time	
  spent	
  
immobile	
  compared	
  to	
  saline	
  controls	
  (p<0.01).	
  Treatment	
  with	
  1.0	
  mg/kg	
  of	
  
PD149163	
  also	
  significantly	
  decreased	
  the	
  time	
  spent	
  immobile	
  in	
  comparison	
  to	
  
saline	
  control	
  animals	
  (p<0.05).	
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Figure 3: Comparison of Controls: Immobility in the Final Four Minutes

Figure	
  3	
  represents	
  the	
  mean	
  for	
  the	
  total	
  time	
  spent	
  immobile	
  in	
  the	
  last	
  four	
  
minutes	
  of	
  the	
  testing	
  session	
  for	
  the	
  imipramine-‐paired	
  control	
  animals	
  versus	
  the	
  
PD14916-‐paired	
  control	
  animals.	
  The	
  mean	
  time	
  spent	
  immobile	
  for	
  the	
  two	
  control	
  
groups	
  did	
  not	
  significantly	
  differ	
  (p>0.05).	
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Figure 4: Imipramine: Immobility in the First 2 Minutes

	
  
Figure	
  4	
  represents	
  the	
  mean	
  for	
  the	
  total	
  time	
  spent	
  immobile	
  in	
  the	
  first	
  2	
  minutes	
  
of	
  the	
  testing	
  session	
  for	
  imipramine-‐	
  and	
  saline-‐	
  treated	
  mice.	
  Treatment	
  with	
  1.0	
  
mg/kg	
  of	
  imipramine	
  produced	
  a	
  significant	
  decrease	
  in	
  the	
  time	
  spent	
  immobile	
  
compared	
  to	
  saline	
  treatment	
  (p<0.05).	
  	
  Treatment	
  with	
  10.0	
  mg/kg	
  of	
  imipramine	
  
also	
  significantly	
  decreased	
  the	
  time	
  spent	
  immobile	
  in	
  comparison	
  to	
  saline	
  
administration	
  (p<0.0001).	
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Figure 5: PD149163: Immobility in the First 2 Minutes

	
  
Figure	
  5	
  represents	
  the	
  mean	
  for	
  the	
  total	
  time	
  spent	
  immobile	
  in	
  the	
  first	
  2	
  minutes	
  
of	
  the	
  testing	
  session	
  for	
  PD149163-‐	
  and	
  saline-‐	
  treated	
  mice.	
  Administration	
  of	
  0.1	
  
mg/kg	
  of	
  PD149163	
  produced	
  a	
  significant	
  decrease	
  in	
  the	
  time	
  spent	
  immobile	
  in	
  
comparison	
  to	
  saline	
  administration	
  	
  (p<0.01).	
  Treatment	
  with	
  1.0	
  mg/kg	
  of	
  
PD149163	
  did	
  not	
  significantly	
  alter	
  the	
  time	
  spent	
  immobile	
  (p>0.05).	
  	
  
	
  

47

Figure 6: Comparison of Controls: Immobility in the First 2 Minutes

	
  
Figure	
  6	
  represents	
  the	
  mean	
  for	
  the	
  total	
  time	
  spent	
  immobile	
  in	
  the	
  first	
  2	
  minutes	
  
of	
  the	
  testing	
  session	
  for	
  the	
  imipramine-‐paired	
  versus	
  PD149163-‐paired	
  control	
  
animals.	
  The	
  mean	
  time	
  spent	
  immobile	
  for	
  the	
  imipramine	
  and	
  PD149163	
  paired	
  
control	
  animals	
  did	
  not	
  significantly	
  differ	
  (p>0.05).	
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Figure 7: Imipramine: Latency to First Episode of Immobility

Figure	
  7	
  represents	
  the	
  mean	
  latency	
  to	
  the	
  first	
  episode	
  of	
  immobility	
  for	
  the	
  
imipramine-‐	
  and	
  saline-‐treated	
  mice.	
  Administration	
  of	
  1.0	
  mg/kg	
  of	
  imipramine	
  
did	
  not	
  significantly	
  alter	
  the	
  latency	
  to	
  the	
  first	
  episode	
  of	
  immobility	
  (p>0.05).	
  
Treatment	
  with	
  10.0	
  mg/kg	
  produced	
  a	
  significant	
  increase	
  in	
  the	
  latency	
  to	
  the	
  first	
  
episode	
  of	
  immobility	
  (p<0.01).	
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Figure 8: PD149163: Latency to First Episode of Immobility

	
  
Figure	
  8	
  represents	
  the	
  mean	
  latency	
  to	
  the	
  first	
  episode	
  of	
  immobility	
  for	
  the	
  
PD149163-‐	
  and	
  saline-‐	
  treated	
  mice.	
  Application	
  of	
  0.1	
  mg/kg	
  or	
  1.0	
  mg/kg	
  
PD149163	
  failed	
  to	
  produce	
  a	
  significant	
  change	
  in	
  the	
  latency	
  to	
  the	
  first	
  episode	
  of	
  
immobility	
  versus	
  saline	
  administration	
  (p>0.05).	
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Figure 9: Comparison of Controls: Latency to First Episode of Immobility

Figure	
  9	
  represents	
  the	
  mean	
  latency	
  to	
  the	
  first	
  episode	
  of	
  immobility	
  for	
  
imipramine-‐paired	
  and	
  PD149163-‐paired	
  control	
  animals.	
  The	
  mean	
  latencies	
  to	
  
the	
  first	
  episode	
  of	
  immobility	
  for	
  the	
  PD149163-‐	
  and	
  imipramine-‐paired	
  control	
  
groups	
  did	
  not	
  significantly	
  differ	
  (p>0.05).	
  	
  
	
  
	
  
	
  
	
  
	
  

51

	
  

Figure 10: Imipramine: Total Distance Traveled

Figure	
  10	
  represents	
  the	
  mean	
  for	
  the	
  total	
  distance	
  traveled	
  during	
  the	
  open	
  field	
  
test	
  for	
  imipramine-‐	
  and	
  saline-‐treated	
  mice.	
  Administration	
  of	
  1.0	
  mg/kg	
  of	
  
imipramine	
  did	
  not	
  significantly	
  alter	
  the	
  total	
  distance	
  traveled	
  versus	
  saline	
  
administration	
  (p>0.05).	
  Treatment	
  with	
  10.0	
  mg/kg	
  of	
  imipramine	
  produced	
  a	
  
significant	
  decrease	
  in	
  the	
  total	
  distance	
  traveled	
  versus	
  saline	
  administration	
  
(p<0.01).	
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Figure 11: PD149163: Total Distance Traveled

	
  
Figure	
  11	
  represents	
  the	
  mean	
  for	
  the	
  total	
  distance	
  traveled	
  during	
  the	
  open	
  field	
  
test	
  for	
  PD149163-‐	
  and	
  saline-‐treated	
  mice.	
  Treatment	
  with	
  0.1	
  mg/kg	
  of	
  PD149163	
  
did	
  not	
  significantly	
  affect	
  the	
  total	
  distance	
  traveled	
  in	
  comparison	
  to	
  saline-‐
treated	
  animals.	
  Administration	
  of	
  1.0	
  mg/kg	
  of	
  PD149163	
  produced	
  a	
  significant	
  
reduction	
  in	
  the	
  total	
  distance	
  traveled	
  versus	
  saline	
  control	
  animals	
  (p<0.05).	
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Figure 12: Comparison of Controls: Total Distance Traveled

Figure	
  12	
  represents	
  the	
  mean	
  for	
  the	
  total	
  distance	
  traveled	
  for	
  imipramine-‐paired	
  
and	
  PD149163-‐paired	
  control	
  animals.	
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DISCUSSION

In the final four minutes of the testing session, the time period analyzed in a
typical forced swim test procedure, imipramine produced a significant decrease in the
time spent immobile at the 10.0mg/kg dose, while failing to produce a significant
decrease at the 1.0 mg/kg dose. These results are consistent with previous experiments
where doses of 1.0 mg/kg failed to produce reductions in immobility while the 10.0
mg/kg dose produced consistent reductions, even after the animals were given the test
substances daily for 14 consecutive days (Kitamura et al., 2004). PD149163 produced
significant decreases in immobility in the final four minutes of the testing session at both
the 0.1 mg/kg and 1.0 mg/kg doses. The results of this experiment provide the first report
of the effects of PD149163 in the forced swim test, although previous research has
demonstrated the ability of intracranial administration of the full neurotensin peptide to
reduce immobility in rats (Cervo et al., 1992). The mean time spent immobile in the final
four minutes of the testing session for the PD149163- and imipramine-paired saline
control groups did not significantly differ, indicating that any observed differences
between the treatment groups and their saline counterparts were not due to abnormalities
in the controls their results were compared to.
According to the original forced swim test procedures, the first two minutes are
typically excluded from analysis as animals generally display little immobility during this
time period (Castagne et al., 2009). However, the present study sought to examine if
differences in these first two minutes exist. Both doses of imipramine produced
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significant reductions in the time spent immobile in the first two minutes, while only the
10.0 mg/kg did in the final four minutes of the session. Only the 0.1 mg/kg dose of
PD149163 produced a significant decrease in immobility in the first two minutes, while
both doses significantly reduced immobility in the final four minutes. These results
indicate that additional inquiry may be needed into the delay to the onset of these
substances, and how the therapeutic response differs with varying pretreatment times. In
the first two minutes no differences were observed between the imipramine- and
PD149163- paired saline controls, indicating again that any observed differences were
not due to abnormalities in control group performance.
While the latency to the first episode of immobility is not a result frequently
reported in a forced swim test, the present study sought to examine whether either of the
test substances would cause a delay in the animals adoption of the immobile posture. If
the duration of immobility in the forced swim test can be considered an index of
behavioral despair, and a reduction in this behavior is an indication of therapeutic
efficacy, then a protracted period of escape-related or swimming behaviors before the
animal adopts the passive posture may also be a possible manifestation of antidepressant
effects. Imipramine significantly increased the latency to the onset of immobility at the
10.0 mg/kg dose, while the 1.0 mg/kg dose of imipramine and both doses of PD149163
failed to produce a significant effect. However, the differences between the results from
the first two minutes and the final four minutes of the testing session indicate the
possibility that altering pretreatment time courses may yield different results. The
latencies to the onset of the first immobility displayed by the imipramine- and
PD149163-paired control mice did not differ, indicating again that any observed
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differences between the treatment groups and their controls were not due to abnormalities
in the control groups.
The reasons for excluding the first two minutes of the testing session from
analysis are not adequately explained in any version of the protocol encountered during
the course of this experiment. In Porsolt’s forced swim test protocol he simply states that
animals do not spend very much time immobile in the first two minutes, and the more
stable levels of immobility in the final four minutes of the testing session provide a more
reliable baseline for making comparisons between treatment groups (Castagne et al.,
2010). One possible explanation comes from observing the species differences between
the forced swim test for rats and the forced swim test for mice. In the rat protocol as
described by Porsolt, animals are subjected to two periods of swimming and three
administrations of the test substances. The first day is used as a habituation period
wherein the animals are placed in the apparatus for 15 minutes and no behavioral
recording occurs. Following the habituation period the animals receive an injection of the
test substance. The next day, 4 hours before the testing session, the animals receive
another administration of the test substance. Finally, 30 minutes before the test, the
animals receive a third and final administration of the test substance. The testing session
lasts for a total of 5 minutes and all of the behavior is recorded. The habituation period is
performed in rats because unlike mice they perform other behaviors like diving that
significantly alter baseline immobility times. Therefore, subjecting them to the
habituation period allows for higher levels of immobility on the testing day. Excluding
the first two minutes of the testing session for mice could possibly function as a
habituation period in compensation for the lack of an actual pre-test habituation period.
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On the other hand, the habituation period performed in the rat protocol has generated
some criticism. This initial exposure could actually reflect a learning period, allowing the
rat to learn the most efficient way to survive in this inescapable environment. In that
sense, immobility is an adaptive behavioral mechanism and may not be considered an
index of despair. Alternatively, an increase in immobility on the second day in the rat
protocol could exemplify learned helplessness, wherein the animal has actually learned
that the environment is inescapable and ceases efforts to escape (Petit-Demouliere et al.,
2005). When mice are exposed to a pre-test habituation like the one performed in the
typical rat protocol, the experienced animals exhibit higher levels of immobility than
naïve animals when compared during a 5 minute testing session (Alcaro et al., 2002).
This pre-exposure could also either be a case of adaptation, or stress induced learned
helplessness. Either way, skipping the pre-test habituation session in the mouse protocol
removes this possible source of influence, and may therefore provide for more stable
behavior in mice. Whatever the case, it is impossible to infer any absolute evidence of
human affective behavioral states from observing animal behavior. What we do know is
that drugs with antidepressant effects in humans reduce the amount of time rats and mice
spend immobile in this task, despite the species differences in protocols.
In the locomotor assessment, none of the drug treatments produced an increase in
general locomotor behavior. This is an important fact to note, as this particular screening
model is prone to producing false positives. These results indicate that the reductions in
immobility observed in the forced swim test were not due to a stimulant-like effect, and
may actually represent potential antidepressant effects of the test substances. The 10.0
mg/kg dose of imipramine and the 1.0 mg/kg dose of PD149163 actually produced a
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decrease in the total distance traveled during the locomotor assessment. While the ability
of imipramine to reduce locomotor behavior has been noted (Gutierrez-Garcia et al.,
2009), one possible explanation for the observed reduction in locomotor behavior is the
action of imipramine, or it’s metabolite desipramine, as an antagonist at the histamine H1
receptor (Owens et al., 1997; Sugar et al., 1984). The sedative effects of tricyclic
antidepressant medications are well documented and thus they are frequently prescribed
as sleep aids (Plattner et al., 2011).
Previous research has shown that mice lacking the NTS1 receptor exhibit higher
levels of locomotor activity than their wild type counter parts (Li et al., 2010). This
hyperactivity has been attributed to disregulation of dopamine transmission in the
striatum as a result of the deletion of NTS1 receptor. In wild type mice, administration of
neurotensin or neurotensin analog drugs such as PD149163 effectively block increases in
locomotor behavior in response to stimulant treatment (Kalivas et al., 1984; Feifel et al.,
2008), an effect that is thought to be due to possible interactions between the NTS1 and
D2 receptors (Tanganelli et al., 1993; Fuxe et al., 1992; Li et al., 1995). Although it is
unclear precisely how neurotensin modulates locomotor behavior under normal
circumstances, the possibility for influences exist through it’s influence on mesolimbic
dopaminergic functioning, and input from the nucleus accumbens to cortical
glutamatergic neurons and their input to feedback loops returning to midbrain dopamine
producing nuclei (Antonelli et al., 2002).
This study has provided the fist indication that the neurotensin analog drug
PD149163 exhibits antidepressant-like effects in the forced swim test. Additional
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research into the time course, and the effects of this compound at varying doses will
provide more insight into the potential to use PD149163 as a novel antidepressant drug.
These findings, coupled with the other evidence gathered thus far into the therapeutic
potential of the neurotensin system indicate that neurotensin analog drugs like PD149163
may have the potential to alleviate the symptoms of depression in human patients.
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APPENDIX B

anim

treatment

weight

date

al ID

Time

TI first 2

Latency to

immobile (s)

min.

first 1st

(final 4m)

2/final 4

1

Veh

24

2I11

125.64

56.71

11s/6.3s

2

Veh

27

2I11

145.72

59.45

10.6/1.73

3

Veh

24

2I11

143.11

52.1

3.68/7.28

4

Imipramine

24

2I11

139.89

59.3

6.33/0

24

2I11

41.75

18.76

33.73/11.15

26

2I11

62.29

11.82

63.48/28.85

7

PD 0.1mg/kg 25

2I11

110.82

19.82

11.28/18.56

8

PD 0.1mg/kg 23

2I11

122.32

20.16

76.5/4.91

9

PD 0.1mg/kg 25

2I11

69.85

7.31

83.13/35.48

1.0 mg/kg
5

Imipramine
1.0 mg/kg

6

Imipramine
1.0 mg/kg

71

10

Veh

25

2I11

130.61

25.52

42.58/0

11

Veh

24

2I11

173.3

24.2

76.23/0

12

Veh

26

2I11

89.85

46.53

63.73/0

13

Imipramine

23

2I11

72.3

14.59

38.52/26.4

25

2I11

143.45

24.32

58.51/3.13

26

2I11

143.8

20.3

65.88/1.63

16

PD 0.1mg/kg 25

2I11

115.55

0

126.8/5.86

17

PD 0.1mg/kg 27

2I11

136.84

42.45

5.23/12.83

18

PD 0.1mg/kg 25

2I11

149.03

24.33

69.25/0

19

Imipramine

24

2I11

82.29

22.98

43.16/19.15

26

2I11

73.18

10.02

6.23/24.68

1.0 mg/kg
14

Imipramine
1.0 mg/kg

15

Imipramine
1.0 mg/kg

1.0 mg/kg
20

Imipramine
1.0 mg/kg

21

Veh

25

2I11

138.59

44.93

3.33/0

22

PD 0.1mg/kg 24

2I11

120.91

18.84

65.65/0

72

23

PD 0.1mg/kg 25

2I11

83.69

21.89

39.8/26.92

24

Veh

23

2I11

152.22

27.54

74.82/0

25

Veh

26

2I12

188.7

48.71

69.85/0

26

Veh

25

2I12

163.32

49.38

7.98/1.81

27

Veh

26

2I12

183.83

56.86

25.83/0

28

Imipramine

25

2I12

0

0

360

24

2I12

63.44

14.43

65.21/6.38

24

2I12

136.62

29.77

53.83/0

31

PD 1.0mg/kg 23

2I12

101.49

2.06

75.26/34.75

32

PD 1.0mg/kg 25

2I12

111.79

26.79

1.18/15.53

33

PD 1.0mg/kg 28

2I12

93.58

23.58

0/25.35

34

Veh

23

2I12

119.95

47.45

32.99/4.18

35

Veh

23

2I12

146.67

16.67

80.61/0

36

Veh

27

2I12

194.39

35.87

3.53/0

37

Imipramine

25

2I12

80.58

8.97

88.16/14.46

10.0 mg/kg
29

Imipramine
10.0 mg/kg

30

Imipramine
10.0 mg/kg

73

10.0 mg/kg
38

Imipramine

24

2I12

64.01

0

128.56

24

2I12

35.39

0

150.11

40

PD 1.0mg/kg 25

2I12

137.65

46.09

0/0

41

PD 1.0mg/kg 24

2I12

155.76

32.15

0/0

42

PD 1.0mg/kg 24

2I12

123.59

16.25

74.36/0

43

Imipramine

24

2I12

112.54

0

122.78/2.78

23

2I12

60.12

2.58

110.68/29.8

10.0 mg/kg
39

Imipramine
10.0 mg/kg

10.0 mg/kg
44

Imipramine
10.0 mg/kg

1

45

Veh

23

2I12

136.44

35.96

28.8/7.21

46

PD 1.0mg/kg 24

2I12

119.85

44.05

0/0

47

PD 1.0mg/kg 24

2I12

138.14

15

0/4.21

48

Veh

2I12

140.4

31.64

15.13/5.73

24

74

